Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SGLT2 inhibitors, an Accomplished Development in Field of Medicinal Chemistry: an Extensive Review
Anirudh Manoj, Subham Das, A Ramachandran, et al.
Future Medicinal Chemistry (2020) Vol. 12, Iss. 21, pp. 1961-1990
Closed Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Carbohydrate-based drugs launched during 2000−2021
Xin Cao, Xiaojing Du, Heng Jiao, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 10, pp. 3783-3821
Open Access | Times Cited: 150
A comprehensive review on Sesamum indicum L.: Botanical, ethnopharmacological, phytochemical, and pharmacological aspects
Ajay Mili, Subham Das, Krishnadas Nandakumar, et al.
Journal of Ethnopharmacology (2021) Vol. 281, pp. 114503-114503
Closed Access | Times Cited: 48
Crataegus pinnatifida: A botanical, ethnopharmacological, phytochemical, and pharmacological overview
Ruiyu Li, Fei Luan, Yunyan Zhao, et al.
Journal of Ethnopharmacology (2022) Vol. 301, pp. 115819-115819
Closed Access | Times Cited: 29
New treatment approaches for Alzheimer’s disease: preclinical studies and clinical trials centered on antidiabetic drugs
Andreas P. Katsenos, Athena S. Davri, Yannis V. Simos, et al.
Expert Opinion on Investigational Drugs (2021) Vol. 31, Iss. 1, pp. 105-123
Closed Access | Times Cited: 26
Click Reaction Inspired Enzyme Inhibitors in Diabetes Care: An Update in the Field of Chronic Metabolic Disorder
Deeksha Mudgal, Nisha Yadav, Gaurav Kumar Srivastava, et al.
Current Pharmaceutical Design (2024) Vol. 31, Iss. 4, pp. 261-291
Closed Access | Times Cited: 3
The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review
Subham Das, A Ramachandran, Sumit Birangal, et al.
Medicine in Drug Discovery (2021) Vol. 10, pp. 100085-100085
Open Access | Times Cited: 22
Bexagliflozin: a comprehensive review of a recently approved SGLT2 inhibitor for the treatment of type 2 diabetes mellitus
Ryan L. Bassett, Giovanni Gallo, Kim-Phuong N. Le, et al.
Medicinal Chemistry Research (2024) Vol. 33, Iss. 8, pp. 1354-1367
Open Access | Times Cited: 2
Repurposing of Omarigliptin as a Neuroprotective Agent Based on Docking with A2A Adenosine and AChE Receptors, Brain GLP-1 Response and Its Brain/Plasma Concentration Ratio after 28 Days Multiple Doses in Rats Using LC-MS/MS
Bassam M. Ayoub, Haidy E. Michel, Shereen Mowaka, et al.
Molecules (2021) Vol. 26, Iss. 4, pp. 889-889
Open Access | Times Cited: 16
Recent Advancement of Pyrazole Scaffold Based Neuroprotective Agents: A Review
Faheem Hyder Pottoo, Alex Joseph, Subham Das, et al.
CNS & Neurological Disorders - Drug Targets (2021) Vol. 21, Iss. 10, pp. 940-951
Closed Access | Times Cited: 16
Putative protective effects of sodium-glucose cotransporter 2 inhibitors on atrial fibrillation through risk factor modulation and off-target actions: potential mechanisms and future directions
Syona S Shetty, Andrew Krumerman
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 12
Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis
Sagar Dholariya, Siddhartha Dutta, Ragini Singh, et al.
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 18, pp. 2187-2198
Closed Access | Times Cited: 6
SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus
Nikola Lukić, Mirjana Mačvanin, Zoran Gluvić, et al.
Current Medicinal Chemistry (2023) Vol. 31, Iss. 30, pp. 4781-4806
Closed Access | Times Cited: 5
Dual-Target Compounds against Type 2 Diabetes Mellitus: Proof of Concept for Sodium Dependent Glucose Transporter (SGLT) and Glycogen Phosphorylase (GP) Inhibitors
Ádám Sipos, Eszter Szennyes, Nikolett Éva Hajnal, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 4, pp. 364-364
Open Access | Times Cited: 12
Mechanistic and Etiological Similarities in Diabetes Mellitus and Alzheimer’s Disease: Antidiabetic Drugs as Optimistic Therapeutics in Alzheimer’s Disease
Subham Das, A Ramachandran, Debojyoti Halder, et al.
CNS & Neurological Disorders - Drug Targets (2022) Vol. 22, Iss. 7, pp. 973-993
Closed Access | Times Cited: 8
Crosstalk Between Covid-19 and Associated Neurological Disorders: A Review
A Ramachandran, Subham Das, Alex Joseph
Current Neuropharmacology (2021) Vol. 19, Iss. 10, pp. 1688-1700
Open Access | Times Cited: 11
Discovery of Orally Bioavailable FmlH Lectin Antagonists as Treatment for Urinary Tract Infections
Amarendar Reddy Maddirala, Kevin O. Tamadonfar, Jerome S. Pinkner, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 5, pp. 3668-3678
Closed Access | Times Cited: 1
Chimeras Derived from a P2Y14 Receptor Antagonist and UDP-Sugar Agonists for Potential Treatment of Inflammation
Zhiwei Wen, Asmita Pramanik, Sarah A. Lewicki, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 10, pp. 3255-3278
Closed Access | Times Cited: 1
A review on the medicinal chemistry of sodium glucose co-transporter 2 inhibitors (SGLT2-I): Update from 2010 to present
Jonali Ramani, Harshil Shah, Vivek K. Vyas, et al.
European Journal of Medicinal Chemistry Reports (2022) Vol. 6, pp. 100074-100074
Open Access | Times Cited: 7
Structure-Activity Relationship Insight of Naturally Occurring Bioactive Molecules and Their Derivatives Against Non-Small Cell Lung Cancer: A Comprehensive Review
Subham Das, Shubham Roy, Seikh Batin Rahaman, et al.
Current Medicinal Chemistry (2022) Vol. 29, Iss. 39, pp. 6030-6062
Closed Access | Times Cited: 5
Telescoped lithiation, C-arylation and methoxylation in flow-batch hybrid toward the synthesis of canagliflozin
Dominik Polterauer, Jason D. Williams, Christopher A. Hone, et al.
Tetrahedron Letters (2021) Vol. 82, pp. 153351-153351
Closed Access | Times Cited: 7
Advances in computer-aided drug design for type 2 diabetes
Wanqiu Huang, Luyong Zhang, Zheng Li
Expert Opinion on Drug Discovery (2022) Vol. 17, Iss. 5, pp. 461-472
Closed Access | Times Cited: 4
SGLT2 Inhibitors and Kidney Diseases: A Clinical Perspective
Panagiotis Theofilis, Rigas Kalaitzidis
Current Medicinal Chemistry (2022) Vol. 30, Iss. 23, pp. 2595-2603
Closed Access | Times Cited: 3
Empagliflozina, Inibidor do SGLT2 no Tratamento da Diabetes do Tipo 2
Catarina Gamito, Chiara La Guidara, João R. Costa
Boletim da Sociedade Portuguesa de Química (2024), pp. 48-48
Open Access
A PARADIGM SHIFT FOR THE SGLT2 INHIBITORS – TREATING THE HEART WITH ANTI-HYPERGLYCAEMIC DRUGS
Elisabeta Bădilă
FARMACIA (2021) Vol. 69, Iss. 5, pp. 837-848
Open Access | Times Cited: 1
Industrial-Scale Preparation of a Key Intermediate for the Manufacture of Therapeutic SGLT2 Inhibitors
Lei Huang, Yi Zhang, Xiao-Hui Shan, et al.
Pharmaceutical Fronts (2022) Vol. 04, Iss. 04, pp. e237-e243
Open Access
Page 1 - Next Page

Scroll to top